If you're running an addiction treatment program in 2026, you're operating under a regulatory framework that was fundamentally reshaped by COVID-19. The pandemic forced rapid changes to how SUD treatment could be delivered, and the American Society of Addiction Medicine (ASAM) issued guidance that not only helped providers navigate the crisis but permanently altered the landscape of care delivery. The ASAM COVID-19 guidelines for addiction treatment providers weren't just emergency recommendations; they became the foundation for lasting policy changes around telehealth, medication access, and service flexibility that define your operational reality today.
The challenge for clinical directors and program operators now isn't remembering what happened during the pandemic. It's knowing which flexibilities are still in effect, which regulations have reverted, and what compliance looks like when federal agencies have made some changes permanent while letting others expire. This article synthesizes ASAM's COVID-era guidance and maps it to your current regulatory obligations in 2026.
ASAM's COVID-19 Guidance Framework for SUD Treatment Providers
When the pandemic hit in early 2020, ASAM moved quickly to provide SUD-specific guidance that went beyond generic healthcare infection control. The organization recognized that addiction treatment settings faced unique challenges: patients in early recovery couldn't simply pause treatment, residential facilities operated as congregate settings with heightened transmission risk, and medication-assisted treatment required ongoing prescribing and dispensing that couldn't stop.
ASAM's framework addressed three core domains. First, infection prevention and control measures tailored to residential, outpatient, and opioid treatment program (OTP) settings. Second, service delivery modifications that maintained treatment continuity while reducing transmission risk, including the rapid expansion of telehealth and remote prescribing. Third, patient safety protocols that accounted for how COVID-19 infection intersected with active substance use disorder treatment.
The guidance wasn't static. ASAM updated recommendations as the pandemic evolved, federal agencies issued emergency waivers, and clinical evidence accumulated about COVID-19's specific impact on patients with SUD. For operators, this created a moving target of compliance requirements that shifted every few months throughout 2020 and 2021.
Telehealth Expansion: What ASAM Recommended and What's Permanent
Perhaps the most transformative element of ASAM COVID guidelines for SUD treatment centers was the endorsement of telehealth as a primary service delivery modality. Before COVID-19, most addiction treatment was delivered face-to-face, with telehealth used sparingly and often requiring special justification for reimbursement.
ASAM's COVID guidance supported the use of synchronous video and, when necessary, audio-only telehealth for individual therapy, group counseling, psychiatric evaluation, and ongoing medication management. This aligned with emergency flexibilities issued by DEA, SAMHSA, and CMS that temporarily removed barriers to remote care. The guidance emphasized that telehealth should maintain the same clinical standards as in-person care, including proper documentation, informed consent, and assessment of appropriateness for each patient.
In 2026, much of this telehealth expansion has become permanent, but with important caveats. The Consolidated Appropriations Act of 2023 extended many Medicare telehealth flexibilities, and most state Medicaid programs have maintained expanded telehealth coverage for behavioral health. However, audio-only services face ongoing uncertainty, with some payers requiring video when technically feasible. Programs building hybrid telehealth models need to track state-specific requirements and payer policies that vary significantly.
For operators, the practical implication is clear: telehealth is now a standard component of SUD treatment delivery, not an emergency exception. Your program needs compliant infrastructure, staff training, and documentation systems that support remote service delivery as a permanent operational capability.
Buprenorphine Without In-Person Evaluation: Current Status in 2026
One of the most clinically significant aspects of addiction treatment COVID-19 protocols in 2026 involves buprenorphine prescribing. During the pandemic, DEA issued emergency exemptions allowing practitioners to prescribe buprenorphine via telehealth without an initial in-person evaluation. ASAM strongly supported this flexibility, noting that it removed a critical barrier to MAT access during a period when overdose deaths were surging.
The clinical evidence accumulated during COVID-19 demonstrated that telehealth buprenorphine induction was both safe and effective when conducted by qualified practitioners using proper assessment protocols. Studies showed retention rates comparable to in-person induction, with the added benefit of reaching patients who faced geographic, transportation, or stigma-related barriers to office visits.
In 2026, the regulatory landscape for buprenorphine prescribing has stabilized but remains more flexible than pre-pandemic norms. The DEA has extended telehealth prescribing authority for buprenorphine under specific conditions, though the exact parameters have been subject to rulemaking. Most states allow qualified practitioners to initiate buprenorphine via telehealth, but documentation requirements are strict: providers must conduct a thorough assessment via video (audio-only is generally not sufficient for initiation), document the clinical rationale for remote induction, and establish a treatment plan that includes appropriate follow-up.
For ASAM telehealth MAT COVID recommendations that remain relevant today, the emphasis is on clinical appropriateness rather than blanket permission. Not every patient is suitable for telehealth induction. Providers need to assess for factors like severity of opioid use disorder, co-occurring conditions, support system stability, and patient technological capability. Your program's policies should define clear criteria for when telehealth MAT initiation is appropriate and when in-person evaluation is clinically necessary.
Methadone Take-Home Dose Expansions: Permanent Changes for OTPs
For opioid treatment programs, ASAM's COVID-19 guidance supported SAMHSA's emergency blanket exceptions that dramatically expanded methadone take-home doses. Before the pandemic, federal regulations tightly restricted take-homes based on time in treatment and stability criteria. COVID-19 created an immediate need to reduce daily clinic visits and transmission risk in OTP settings.
SAMHSA's emergency rules allowed stable patients to receive up to 28 days of take-home doses and patients in earlier treatment phases to receive up to 14 days, based on clinical assessment rather than rigid time-in-treatment requirements. ASAM endorsed these changes while emphasizing that clinical judgment should guide individualized take-home decisions, accounting for diversion risk, home storage safety, and patient stability.
The critical development for 2026 is that many of these flexibilities have become permanent. SAMHSA finalized regulations in 2024 that maintained expanded take-home authority, though with more structured clinical criteria than the emergency blanket exceptions. OTPs now have significantly more discretion to provide take-home doses based on individualized assessment, but they must document the clinical rationale and maintain diversion control procedures.
For OTP operators, this means your current take-home protocols should reflect the permanent regulatory framework, not emergency exceptions. Staff need training on the assessment criteria that justify extended take-homes, and your documentation systems must capture the clinical decision-making process. This is an area where the COVID-19 impact on addiction treatment ASAM guidance created lasting operational change that requires updated policies and procedures.
Infection Control Standards for Residential and Congregate SUD Settings
ASAM's COVID-19 guidance included detailed recommendations for infection control in residential treatment facilities, recovery housing, and other congregate settings where SUD treatment occurs. These recommendations addressed unique challenges in environments where patients live together, share common spaces, and participate in group activities as a core component of treatment.
The guidance covered screening protocols for new admissions, quarantine procedures for exposed or symptomatic patients, cohorting strategies to separate COVID-positive patients from others, PPE requirements for staff, and environmental cleaning standards. ASAM emphasized that infection control measures needed to be balanced against therapeutic community principles and the clinical risks of isolating patients in early recovery.
While the acute COVID-19 emergency has passed, many of these infection control principles remain relevant for respiratory illness preparedness in 2026. Residential programs should maintain protocols for managing infectious disease outbreaks, including clear criteria for when to implement enhanced precautions, how to manage symptomatic patients without disrupting treatment continuity, and staff training on infection prevention.
For operators planning to open new treatment facilities, facility design should now incorporate lessons from COVID-19. This includes adequate space for medical isolation when needed, HVAC systems that support infection control, and layouts that allow flexible use of space based on census and health status. State licensing agencies increasingly expect residential programs to have documented infectious disease management plans as part of standard operations.
COVID-19 and SUD Intersection: Clinical Considerations That Persist
ASAM's guidance addressed not just operational changes but the clinical intersection of COVID-19 infection and substance use disorder treatment. The organization highlighted that patients with active SUD faced elevated COVID-19 risk due to factors like smoking, stimulant use affecting cardiovascular health, and social determinants that increased exposure risk.
The guidance also addressed how to manage patients who contracted COVID-19 while in treatment. For patients on methadone or buprenorphine, ASAM emphasized the importance of maintaining MAT continuity even when patients were ill, noting that withdrawal could complicate COVID-19 recovery and increase overdose risk. For patients in residential treatment, the guidance supported medical monitoring and coordination with healthcare providers to manage both conditions simultaneously.
Perhaps most significantly, ASAM documented the parallel overdose surge that occurred during the pandemic. The COVID-19 impact on addiction treatment ASAM tracked went beyond infection control to encompass the broader crisis of treatment disruption, social isolation, and fentanyl proliferation that drove overdose deaths to record levels in 2020 and 2021. This context informed ASAM's strong advocacy for maintaining treatment access through policy flexibility.
In 2026, the clinical lessons remain relevant. Programs should maintain protocols for managing patients with acute illness while in treatment, understanding that interrupting SUD care creates significant risk. The overdose crisis that accelerated during COVID-19 continues, making treatment access and retention more critical than ever.
SUD Treatment Center COVID Infection Control Guidelines: Ongoing Relevance
While COVID-19 is no longer a public health emergency, SUD treatment center COVID infection control guidelines established during the pandemic have evolved into broader respiratory illness preparedness protocols. ASAM's framework provides a template that programs can adapt for influenza, RSV, and future novel pathogens.
Current best practice includes maintaining policies for symptomatic patient and staff screening, having access to testing capabilities, establishing clear return-to-program criteria after illness, and training staff on standard and transmission-based precautions. These protocols should be integrated into your program's health and safety policies, not treated as pandemic-specific documents.
For programs operating intensive outpatient services, infection control is less complex than residential settings but still requires clear policies. When should symptomatic patients participate via telehealth rather than in-person? What cleaning protocols apply to group therapy spaces? How do you balance infection risk with the therapeutic benefit of in-person connection? These operational questions need documented answers.
The documentation burden has also increased. Payers and licensing agencies expect programs to demonstrate infection control competency as part of standard operations. Your EHR system should support tracking of health screenings, exposure documentation, and service delivery modifications related to health status.
What's Permanent vs. What Sunset: The 2026 Regulatory Landscape
The most critical question for treatment providers in 2026 is understanding which COVID-era flexibilities are now permanent policy and which have expired or require specific action to maintain. This varies by regulatory domain and jurisdiction, creating a complex compliance landscape.
Permanent or extended changes include:
- Telehealth coverage for behavioral health services under most Medicare and Medicaid programs, though specific service codes and requirements vary by state
- Expanded methadone take-home authority for OTPs under SAMHSA's revised federal regulations
- DEA authority for buprenorphine prescribing via telehealth under defined conditions, though subject to ongoing rulemaking
- Elimination of the DATA 2000 waiver requirement for buprenorphine prescribing (this change was codified in the Consolidated Appropriations Act of 2023, separate from but informed by COVID-19 experience)
- Broader acceptance of telehealth for ASAM criteria level of care assessments, though payer requirements vary
Expired or uncertain flexibilities include:
- Blanket exceptions for audio-only services (most payers now require video when technically feasible)
- Relaxed documentation requirements that applied during the public health emergency
- Some state-specific emergency licensing provisions that allowed out-of-state practitioners to provide telehealth services
- Certain billing code flexibilities that were tied to the public health emergency declaration
For program operators, staying current on these distinctions is not optional. Billing for services under expired emergency authorities creates compliance risk and potential fraud liability. Your billing and clinical teams need regular updates on which policies govern current operations.
Implementing ASAM COVID-Era Lessons in Your 2026 Operations
The practical application of ASAM's COVID-19 guidance in 2026 means integrating lessons learned into standard operating procedures across several domains. First, your service delivery model should include telehealth as a core capability, not an add-on. This requires technology infrastructure, staff competency, and clinical workflows that support seamless transitions between in-person and remote care based on patient needs and clinical appropriateness.
Second, your MAT protocols should reflect current prescribing authority while maintaining rigorous clinical standards. Whether you're operating an OTP with expanded take-home authority or an outpatient program offering telehealth buprenorphine induction, documentation of clinical decision-making is critical. Auditors and licensing agencies expect to see evidence that flexibility is applied with clinical judgment, not as a default approach.
Third, your compliance monitoring should address the hybrid regulatory environment. This means tracking which services are delivered via which modality, ensuring that billing codes match service delivery method, and maintaining documentation that supports medical necessity under current payer policies. For programs operating residential treatment, this also includes maintaining infection control protocols that can be activated when needed.
Fourth, staff training should cover both the clinical and compliance aspects of COVID-era policy changes that are now permanent. Clinicians need to understand when telehealth is clinically appropriate, how to conduct effective remote assessments, and what documentation is required. Administrative staff need to understand billing rules, payer-specific policies, and how to track the regulatory landscape as it continues to evolve.
Looking Forward: Regulatory Agility as a Core Competency
Perhaps the most important lesson from ASAM's COVID-19 guidance and the regulatory changes it influenced is that treatment providers need organizational capacity for regulatory agility. The pandemic demonstrated that policy can change rapidly, and programs that could quickly adapt to new requirements maintained operations while others struggled.
In 2026, this means building systems that can flex as regulations evolve. Your policies and procedures should be living documents that are regularly reviewed and updated. Your leadership team should have clear responsibility for monitoring regulatory changes across federal and state levels. Your technology infrastructure should support operational modifications without requiring complete system overhauls.
This is where many programs benefit from partnership with organizations that specialize in regulatory compliance and operational infrastructure for addiction treatment. Tracking DEA rules, SAMHSA guidance, state-specific telehealth laws, and payer policy changes across multiple insurance contracts is a full-time job that diverts clinical leadership from patient care.
Partner With Experts Who Track the Regulatory Landscape
The regulatory environment for addiction treatment in 2026 reflects the lasting impact of COVID-19 policy changes, but it's far from static. Federal agencies continue to issue guidance, states modify licensing requirements, and payers adjust coverage policies. Staying compliant while optimizing your service delivery model requires both clinical expertise and regulatory monitoring capacity.
ForwardCare partners with addiction treatment providers to navigate this complex landscape. We help programs implement telehealth infrastructure that meets current compliance standards, develop policies and procedures that reflect the latest regulatory requirements, and build operational systems that support both clinical excellence and regulatory agility. Our team tracks the regulatory changes that matter for your program so you can focus on delivering care.
Whether you're updating your program to reflect permanent COVID-era changes, expanding telehealth services, or ensuring your MAT protocols align with current federal and state requirements, we provide the MSO support that keeps your operations compliant and your clinical team focused on patients. Contact ForwardCare to discuss how we can help your program navigate the evolving regulatory landscape and build infrastructure for sustainable, compliant growth in 2026 and beyond.
